Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose Of Review: Current non-invasive tests for evaluating patients with peripheral artery disease (PAD) have significant limitations for early detection and management of patients with PAD and are generally focused on the evaluation of large vessel disease. PAD often involves disease of microcirculation and altered metabolism. Therefore, there is a critical need for reliable quantitative non-invasive tools that can assess limb microvascular perfusion and function in the setting of PAD.
Recent Findings: Recent developments in positron emission tomography (PET) imaging have enabled the quantification of blood flow to the lower extremities, the assessment of the viability of skeletal muscles, and the evaluation of vascular inflammation and microcalcification and angiogenesis in the lower extremities. These unique capabilities differentiate PET imaging from current routine screening and imaging methods. The purpose of this review is to highlight the promising role of PET in the early detection and management of PAD providing a summary of the current preclinical and clinical research related to PET imaging in patients with PAD and related advancement of PET scanner technology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542486 | PMC |
| http://dx.doi.org/10.1007/s11886-023-01904-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abnormal Amyloid-β Duration, Tau, and Neurodegeneration in Cranial Images.
JAMA Netw Open
September 2025
School of Medicine and Public Health, University of Wisconsin-Madison, Madison.
Importance: It is unclear whether the duration of amyloid-β (Aβ) pathology is associated with neurodegeneration and whether this depends on the presence of tau.
Objective: To examine the association of longitudinal atrophy with Aβ positron emission tomography (PET)-positivity (Aβ+) and the estimated duration of Aβ+ (Aβ+ duration), controlling for tau-positivity.
Design, Setting, And Participants: Data for this longitudinal cohort study were drawn from the Wisconsin Registry for Alzheimer Prevention and the Wisconsin Alzheimer Disease Research Center Clinical Core Study.
Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer Ga-pentixafor-c(RGDfK) for PET-CT imaging.
Eur J Nucl Med Mol Imaging
September 2025
Department of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China.
Objective: CXCR4 and integrin αβ play important roles in tumor biology and are highly expressed in multiple types of tumors. This study aimed to synthesize, preclinically evaluate, and clinically validate a novel dual-targeted PET imaging probe Ga-pentixafor-c(RGDfK) for its potential in imaging tumors.
Methods: The effects of Ga-pentixafor-c(RGDfK) on cell viability, targeting specificity, and affinity were assessed in the U87MG cells.
[F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics.
Eur J Nucl Med Mol Imaging
September 2025
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Purpose: Cardiac noradrenergic denervation visualized by meta-[I]iodobenzylguanidine ([I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[F] fluorobenzylguanidine ([F]MFBG) PET demonstrated favorable imaging characteristics compared with [I]MIBG scintigraphy for neuroendocrine tumors. We assessed [F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.
View Article and Find Full Text PDFPrognostic value of multiparameter [Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer.
Eur J Nucl Med Mol Imaging
September 2025
Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.
Purpose: In this retrospective study, whether [Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers can predict the progression-free survival (PFS) and overall survival (OS) of patients with advanced pancreatic cancer was investigated.
Methods: Fifty-one patients who underwent [Ga]Ga-DOTA-FAPI-04 PET/MR scans before first-line chemotherapy were recruited. Imaging biomarkers, including the maximum tumor diameter, minimum apparent diffusion coefficient (ADC), maximum and mean standardized uptake values (SUV and SUV), fibroblast activation protein- (FAP-) positive tumor volume (FTV and W-FTV) and total lesion FAP expression (TLF and W-TLF), were recorded for primary and whole-body tumors.
Right Ventricle-Dominant Cardiac Sarcoidosis Diagnosed Using a Multimodal Approach.
JACC Case Rep
September 2025
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Background: Cardiac sarcoidosis (CS) usually affects the left ventricle and presents with nonspecific features like conduction abnormalities and ventricular arrhythmias. However, right ventricle (RV)-dominant involvement has been increasingly reported, making diagnosis difficult.
Case Summary: A 55-year-old man presented with palpitations.